AHSCT awakens EBV in MS, yet relapse remains at bay
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
A new study seeks to understand the role of B cells and EBV in the development of MS.
New Australian research has shed light on unique changes in B cells in women with MS, creating avenues for understanding why MS affects more women than men.
New Australian research has found a link between EBV infection and MS risk genes which will enhance understanding of the role of EBV at a cellular level.
Professor Michael Pender explains more about the anti-EBV treatment 'adoptive T cell immunotherapy' that has shown promise for people with progressive MS in his clinical trial.
World-first clinical trial shows new anti-EBV treatment appears safe and may help progressive MS.